研究 COVID-19 奥密克戎变异株的侵袭性和可能的治疗选择建议。
Investigating the aggressiveness of the COVID-19 Omicron variant and suggestions for possible treatment options.
机构信息
Department of Respiratory Medicine, Kanazawa University, Ishikawa, Japan.
Department of Respiratory Medicine, Kanazawa University, Ishikawa, Japan.
出版信息
Respir Med. 2022 Jan;191:106716. doi: 10.1016/j.rmed.2021.106716. Epub 2021 Dec 14.
Abstract
The COVID-19 pandemic has put a strain on all the healthcare systems around the world. The World Health Organization (WHO) stated that the "highly mutated" Omicron variant, known as B.1.1.529, could represent a very high global risk of sudden increases in infections. As a result, it is urgently necessary to explore the most suitable treatments for this variant. The purpose of the study was to investigate the currently available studies regarding the Omicron variant and try to identify any potentially effective therapies for the Omicron variant.
摘要
COVID-19 大流行给全球各地的医疗体系带来了压力。世界卫生组织（WHO）表示，被称为 B.1.1.529 的“高度突变”奥密克戎变体可能代表着感染突然激增的极高的全球风险。因此，迫切需要探索针对这种变体的最合适的治疗方法。本研究旨在调查目前关于奥密克戎变体的研究，并试图确定针对奥密克戎变体的任何潜在有效疗法。
相似文献
1
Investigating the aggressiveness of the COVID-19 Omicron variant and suggestions for possible treatment options.研究 COVID-19 奥密克戎变异株的侵袭性和可能的治疗选择建议。
Respir Med. 2022 Jan;191:106716. doi: 10.1016/j.rmed.2021.106716. Epub 2021 Dec 14.
2
Effectiveness of a Third Dose of mRNA Vaccines Against COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance - VISION Network, 10 States, August 2021-January 2022.在德尔塔和奥密克戎变异株流行期间，mRNA 疫苗加强针在成年人中的 COVID-19 相关急诊和紧急护理就诊和住院方面的效果 - VISION 网络，10 个州，2021 年 8 月至 2022 年 1 月。
MMWR Morb Mortal Wkly Rep. 2022 Jan 21;71(4):139-145. doi: 10.15585/mmwr.mm7104e3.
3
Editorial: The 2022 World Health Organization (WHO) Priority Recommendations and Response to the Omicron Variant (B.1.1.529) of SARS-CoV-2.社论：2022 年世界卫生组织（WHO）关于 SARS-CoV-2 奥密克戎变异株（B.1.1.529）的优先推荐意见和应对措施。
Med Sci Monit. 2022 Feb 1;28:e936199. doi: 10.12659/MSM.936199.
4
Association Between 3 Doses of mRNA COVID-19 Vaccine and Symptomatic Infection Caused by the SARS-CoV-2 Omicron and Delta Variants.mRNA COVID-19 疫苗 3 剂接种与 SARS-CoV-2 奥密克戎和德尔塔变异株引起的有症状感染之间的关联。
JAMA. 2022 Feb 15;327(7):639-651. doi: 10.1001/jama.2022.0470.
5
Current evidence on efficacy of COVID-19 booster dose vaccination against the Omicron variant: A systematic review.当前关于 COVID-19 加强针疫苗接种对奥密克戎变异株有效性的证据：系统评价。
J Med Virol. 2022 Jul;94(7):2969-2976. doi: 10.1002/jmv.27697. Epub 2022 Mar 14.
6
Omicron (B.1.1.529) - variant of concern - molecular profile and epidemiology: a mini review.奥密克戎（B.1.1.529）-关注变异株-分子特征和流行病学：简要综述。
Eur Rev Med Pharmacol Sci. 2021 Dec;25(24):8019-8022. doi: 10.26355/eurrev_202112_27653.
7
Audio Interview: Addressing the Omicron Variant of SARS-CoV-2.音频访谈：应对新冠病毒奥密克戎变种
N Engl J Med. 2022 Jan 27;386(4):e16. doi: 10.1056/NEJMe2201214.
8
COVID-19 Boosters This Fall to Include Omicron Antigen, but Questions Remain About Its Value.今年秋季的新冠病毒加强针将包含奥密克戎抗原，但关于其价值仍存在疑问。
JAMA. 2022 Aug 2;328(5):412-414. doi: 10.1001/jama.2022.11252.
9
Outpatient treatment options to address the SARS-CoV-2 variant Omicron.应对 SARS-CoV-2 变异株奥密克戎的门诊治疗选择。
Expert Rev Anti Infect Ther. 2022 Aug;20(8):1129-1133. doi: 10.1080/14787210.2022.2077191. Epub 2022 May 17.
10
More effective vaccines and oral antivirals: Keys for the battle against Omicron.更有效的疫苗和口服抗病毒药物：对抗奥密克戎的关键。
Biosci Trends. 2022 Mar 11;16(1):1-3. doi: 10.5582/bst.2022.01062. Epub 2022 Feb 17.
引用本文的文献
1
Omicron-COVID-19-Related Knowledge in Parkinson's Disease Patients and Their Caregivers: A Cross-sectional Study.帕金森病患者及其照料者中与奥密克戎-新冠病毒相关的知识：一项横断面研究
Ann Neurosci. 2024 Oct 21:09727531241284359. doi: 10.1177/09727531241284359.
2
Social determinants of health predict readmission following COVID-19 hospitalization: a health information exchange-based retrospective cohort study.健康的社会决定因素可预测 COVID-19 住院后的再入院情况：一项基于健康信息交换的回顾性队列研究。
Front Public Health. 2024 Mar 27;12:1352240. doi: 10.3389/fpubh.2024.1352240. eCollection 2024.
3
In Silico Prediction of Functional SNPs Interrupting Antioxidant Defense Genes in Relation to COVID-19 Progression.与COVID-19进展相关的中断抗氧化防御基因的功能性单核苷酸多态性的计算机模拟预测
Biochem Genet. 2025 Feb;63(1):499-525. doi: 10.1007/s10528-024-10705-9. Epub 2024 Mar 9.
4
Development and evaluation of a novel chromium III-based compound for potential inhibition of emerging SARS-CoV-2 variants.一种新型三价铬基化合物对新兴的严重急性呼吸综合征冠状病毒2（SARS-CoV-2）变体潜在抑制作用的研发与评估。
Heliyon. 2023 Sep 9;9(9):e20011. doi: 10.1016/j.heliyon.2023.e20011. eCollection 2023 Sep.
5
Detection of hospital environmental contamination during SARS-CoV-2 Omicron predominance using a highly sensitive air sampling device.使用高灵敏度空气采样设备检测 SARS-CoV-2 奥密克戎流行期间医院环境的污染。
Front Public Health. 2023 Jan 10;10:1067575. doi: 10.3389/fpubh.2022.1067575. eCollection 2022.
6
Is the post-COVID-19 syndrome a severe impairment of acetylcholine-orchestrated neuromodulation that responds to nicotine administration?新型冠状病毒肺炎后综合征是否为乙酰胆碱介导的神经调节严重受损，且对尼古丁给药有反应？
Bioelectron Med. 2023 Jan 18;9(1):2. doi: 10.1186/s42234-023-00104-7.
7
Altered gut microbiota composition in children and their caregivers infected with the SARS-CoV-2 Omicron variant.感染 SARS-CoV-2 奥密克戎变异株的儿童及其照护者肠道微生物群落组成的改变。
World J Pediatr. 2023 May;19(5):478-488. doi: 10.1007/s12519-022-00659-6. Epub 2023 Jan 10.
8
Association between immunity and viral shedding duration in non-severe SARS-CoV-2 Omicron variant-infected patients.非重症奥密克戎变异株 SARS-CoV-2 感染患者的免疫与病毒脱落持续时间的关系。
Front Public Health. 2022 Dec 22;10:1032957. doi: 10.3389/fpubh.2022.1032957. eCollection 2022.
9
The Impact of COVID-19 Pandemic on the Clinical Practice Patterns in Atrial Fibrillation: A Multicenter Clinician Survey in China.新型冠状病毒肺炎大流行对心房颤动临床实践模式的影响：一项中国多中心临床医生调查
J Clin Med. 2022 Oct 31;11(21):6469. doi: 10.3390/jcm11216469.
10
COVID-19 Positive Status is Associated with Increased In-hospital Mortality in Patients with Acute Myocardial Infarction: A Systematic Review and Meta-analysis.新型冠状病毒肺炎阳性状态与急性心肌梗死患者院内死亡率增加相关：一项系统评价和荟萃分析
J Community Hosp Intern Med Perspect. 2022 Sep 9;12(4):17-24. doi: 10.55729/2000-9666.1103. eCollection 2022.
本文引用的文献
1
The emerging role of oxidative stress in complications of COVID-19 and potential therapeutic approach to diminish oxidative stress.氧化应激在2019冠状病毒病并发症中的新作用及减轻氧化应激的潜在治疗方法。
Respir Med. 2021 Oct;187:106605. doi: 10.1016/j.rmed.2021.106605. Epub 2021 Sep 6.
2
The emerging role of cellular senescence in complications of COVID-19.细胞衰老在 COVID-19 并发症中的新作用。
Cancer Treat Res Commun. 2021;28:100399. doi: 10.1016/j.ctarc.2021.100399. Epub 2021 May 15.
3
An Update on Antiviral Therapy Against SARS-CoV-2: How Far Have We Come?抗2019冠状病毒病病毒疗法的最新进展：我们取得了多大的进展？
Front Pharmacol. 2021 Mar 8;12:632677. doi: 10.3389/fphar.2021.632677. eCollection 2021.
4
COVID-19 in cancer patients: risk, clinical features, and management.癌症患者中的 COVID-19：风险、临床特征和管理。
Cancer Biol Med. 2020 Aug 15;17(3):519-527. doi: 10.20892/j.issn.2095-3941.2020.0289.
5
Cytokine Storms: Understanding COVID-19.细胞因子风暴：了解 COVID-19。
Immunity. 2020 Jul 14;53(1):19-25. doi: 10.1016/j.immuni.2020.06.017. Epub 2020 Jun 28.
6
COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: a prospective cohort study.接受化疗或其他抗癌治疗的癌症患者的 COVID-19 死亡率：一项前瞻性队列研究。
Lancet. 2020 Jun 20;395(10241):1919-1926. doi: 10.1016/S0140-6736(20)31173-9. Epub 2020 May 28.
7
Cancer patients and research during COVID-19 pandemic: A systematic review of current evidence.癌症患者和 COVID-19 大流行期间的研究：当前证据的系统评价。
Crit Rev Oncol Hematol. 2020 Jun;150:102972. doi: 10.1016/j.critrevonc.2020.102972. Epub 2020 Apr 22.
8
The pathogenesis and treatment of the `Cytokine Storm' in COVID-19.新型冠状病毒病中“细胞因子风暴”的发病机制与治疗。
J Infect. 2020 Jun;80(6):607-613. doi: 10.1016/j.jinf.2020.03.037. Epub 2020 Apr 10.
Zotero 插件